Merck & Co., Inc. (MRK)

73.78
0.17 0.23
NYSE
Prev Close 73.61
Open 73.51
Day Low/High 73.39 / 74.27
52 Wk Low/High 15.32 / 85.60
Volume 2.89M
Exchange NYSE
Shares Outstanding 2531.38B
Market Cap 184.92B
P/E Ratio 17.80
Div & Yield N.A. (N.A)

Latest News

3 Healthcare Stocks for 3%+ Dividend Yields

3 Healthcare Stocks for 3%+ Dividend Yields

These picks are attractive for value-oriented dividend investors looking for strong current income potential.

A Healthy Outlook for Merck and Its Organon Spinoff

A Healthy Outlook for Merck and Its Organon Spinoff

Organon's management team has deep leadership, operating and financial experience.

What the Fed Said and Did, Robinhood IPO, Trading Ford, Facebook and ServiceNow

What the Fed Said and Did, Robinhood IPO, Trading Ford, Facebook and ServiceNow

Are traders and investors confused? Possibly. Was that the intent? No, but I think Jerome Powell is fine with that.

Happy Thursday Everyone!

Morning folks, once again we've got a slew of earnings reports and at first blush their coming in a tad better than expected from the likes of Nokia , STMicroelectronics , Wolverine World Wide , Textron , Overstock.comĀ  , and Volkswagen (VLKAY). But...

This Retailer Is Marching Toward Kingship

This Retailer Is Marching Toward Kingship

Walgreens Boots Alliance should benefit from an ageing population and increased demand for medications.

2 Small Stocks to Watch as Conditions Ripen for Biotech Merger Deals

2 Small Stocks to Watch as Conditions Ripen for Biotech Merger Deals

Ardelyx Inc. and Rigel Pharmaceuticals look good as stand-alone companies but also could attract suitors.

Jim Cramer: Don't Bet Against Comebacks in This Second Chance Market

Jim Cramer: Don't Bet Against Comebacks in This Second Chance Market

Just like you have to know how to read a room, you have to know how to read a tape and this tape screams 'I'm not done yet.'

Economics for Dummies, Fed Recap, Fun With Jobs Math, Amazon, Buying ServiceNow

Economics for Dummies, Fed Recap, Fun With Jobs Math, Amazon, Buying ServiceNow

The differences in approach between the two most basic strategies for how to grow an economy are as stark as the division they cause among economists.

Stopped Out on Johnson & Johnson but Willing to Buy it Lower

Stopped Out on Johnson & Johnson but Willing to Buy it Lower

Stand aside for now.

Biden Bits, Vaccine Vanguard, Unmasking Folly, Minerd Musings, Ives Inklings

Biden Bits, Vaccine Vanguard, Unmasking Folly, Minerd Musings, Ives Inklings

Among other things, the president works to align Democratic senators to support his massive Covid relief bill.

Jim Cramer: The Rush to Reopen Is Ill-Advised

Jim Cramer: The Rush to Reopen Is Ill-Advised

Only 7% of Texas is vaccinated, or two million people. I don't want to mess with Texas or Texans until that number is higher.

Biotech Isn't Seeing Much Merger Activity, but Here's a Stock to Like

Biotech Isn't Seeing Much Merger Activity, but Here's a Stock to Like

Dynavax Technologies has inked a supply deal related to a Covid-19 vaccine that could greatly increase its revenue stream.

Jim Cramer: What History Tells Us About Bond-Rate Scares Like This

Jim Cramer: What History Tells Us About Bond-Rate Scares Like This

We could have some real pain ahead for some stocks. Five different kinds.

Night-Time Running and Trading, Tech Beatdown, Yellen on Bitcoin, My Nvidia Plan

Night-Time Running and Trading, Tech Beatdown, Yellen on Bitcoin, My Nvidia Plan

Cryptos and cash are both headed for a real fight. For their own existence.

Here's How I'm Going to Fix My Position in Merck

Here's How I'm Going to Fix My Position in Merck

This is my fifth worst performing position in a book that contains 62 open positions.

Turn of the Worm, Treasury Curve, Manchin's Might, Trading Microsoft, Spotify

Turn of the Worm, Treasury Curve, Manchin's Might, Trading Microsoft, Spotify

There is a point where if longer-dated yields move high enough, defensive-minded investors will be drawn from equities to debt securities.

Whoa Baby! Here's How I'm Trading Johnson & Johnson After Earnings

Whoa Baby! Here's How I'm Trading Johnson & Johnson After Earnings

The revenue and earnings beats are nice but that's not what really got me fired up.

Silent Tears, My D.C. Solution, Dogs (and Leaders) of the Dow, 2021 Predictions

Silent Tears, My D.C. Solution, Dogs (and Leaders) of the Dow, 2021 Predictions

In 2021, let's support each other as we fight our way out of this mess. Let's learn how to love, and forget how to hate.

Assessing AstraZeneca in the Fight Against the Virus

Assessing AstraZeneca in the Fight Against the Virus

While there are certainly some things to like about AZN, I don't think this vaccine, nor the UK emergency authorization, make it investable.

How I'm Playing Astra-Zeneca on Vaccine and Acquisition News

How I'm Playing Astra-Zeneca on Vaccine and Acquisition News

I am staying away from this name for now, despite the Alexion acquisition and vaccine promise.

November to Remember, Energy Roars, Janet Yellen, Transition, 8 Breakout Stocks

November to Remember, Energy Roars, Janet Yellen, Transition, 8 Breakout Stocks

Equity markets have run wild since Oct. 30, and it is the more economically sensitive indices that have really taken flight.

Jim Cramer: This Is All Playing Out Like a Stephen King Novel

Jim Cramer: This Is All Playing Out Like a Stephen King Novel

What happens when everyone hunkers down, creating their own de facto stay-in-place lockdown?

Jim Cramer: Health Care Stocks, the Election and the Perfect Setup

Jim Cramer: Health Care Stocks, the Election and the Perfect Setup

Right now, the market is furiously trying to price in a Blue Wave, and the health care sector is getting clobbered. But here's how I think things play out.

Red Monday, Virus Rattles Market, Political Picture, Aerospace & Defense Stocks

Red Monday, Virus Rattles Market, Political Picture, Aerospace & Defense Stocks

This is a major earnings week, electoral risk is real, the virus is already slowing velocity, and the cavalry (fiscal policy) is not coming. Sometimes, circling the wagons is not the worst idea.

Pfizer Is Trading a Lot on Hopes Ahead of Earnings

Pfizer Is Trading a Lot on Hopes Ahead of Earnings

Investors are not positioned for an upside move.

Does 'Aggressive' Bristol-Myers Have the Right Prescription for Investors?

Does 'Aggressive' Bristol-Myers Have the Right Prescription for Investors?

BMY's announced acquisition of MyoKardia for $13B comes less than a year after its purchase of Celgene.

With Q3 Earnings Up Ahead, Can Johnson & Johnson Set the Table?

With Q3 Earnings Up Ahead, Can Johnson & Johnson Set the Table?

I see no reason to flee this name, therefore, I am not.

Veeva and RedHill: 2 Stocks to Consider as They Team Up to Battle Covid-19

Veeva and RedHill: 2 Stocks to Consider as They Team Up to Battle Covid-19

RedHill Biopharma has adopted 'Veeva Vault CDMS', Veeva's modern cloud platform.